These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genetic abnormalities of somatostatin receptors in pituitary tumors. Lania A; Mantovani G; Spada A Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341 [TBL] [Abstract][Full Text] [Related]
5. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991 [TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275 [TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913 [TBL] [Abstract][Full Text] [Related]
10. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030 [TBL] [Abstract][Full Text] [Related]
11. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227 [TBL] [Abstract][Full Text] [Related]
12. [New medical treatments in pituitary adenomas]. Drutel A; Caron P; Archambeaud F Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854 [TBL] [Abstract][Full Text] [Related]
13. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro. Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235 [TBL] [Abstract][Full Text] [Related]